Latest news with #dosimetry
Yahoo
27-06-2025
- Business
- Yahoo
Thermo Fisher Scientific Awarded $94.5 Million DoD Contract for US Navy Dosimetry Systems
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best S&P 500 stocks with huge upside potential. On June 23, Thermo Fisher Scientific announced that it had been awarded a 5-year contract worth $94.5 million by the US Department of Defense (DoD). Under this contract, Thermo Fisher Scientific will supply the US Navy with a next-gen dosimetry system, coupled with updated radiation health and database management software. A workstation in a research lab stocked with laboratory products and services. The US Navy operates the world's most technologically advanced naval fleet and is the largest global user of dosimetry systems for defense purposes. Thermo Fisher Scientific will provide Navy Occupational Dosimetry System/NODS devices and Navy Radiation Exposure Management System/NAVREMS software. These tools are manufactured in Oakwood Village, Ohio, and are crucial for monitoring and managing occupational radiation exposure among Naval personnel. This includes those associated with nuclear-powered Navy assets, nuclear-capable shipyards, various research sites, laboratories, and naval medical facilities. The advanced digital dosimetry devices are designed with integrated beta, gamma, and neutron detection capabilities, which ensures precise and reliable radiation exposure monitoring in demanding environments. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of a high cumulative radioactivity.− Ongoing Phase 2 study is testing the impact of administering a greater proportion of administered radioactivity during early treatment cycles. OXFORD, United Kingdom, June 25, 2025 /PRNewswire/ -- Blue Earth Therapeutics today announced radiation dosimetry results for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. The Phase 1 clinical trial results were presented by Professor James Nagarajah of Radboud University Medical Centre, the Netherlands. Data were evaluated from 34 cycles of treatment across 13 metastatic castrate resistant prostate cancer patients in the radiation dosimetry portion of a Phase 1/2 clinical trial (NCT05413850) of Lutetium (177Lu) rhPSMA-10.1 Injection. The abstract can be found here: The data presented analysed tumour, kidney, salivary gland, and other healthy organ-absorbed radiation doses, and calculated tumour-to-kidney (T:K) and tumour-to salivary gland (T:S) ratios. These data used a tumour dosimetry methodology in which PET or SPECT scans identified lesions for evaluation that is in line with those reported in the literature for other radioligand therapies. Mean tumour-absorbed dose was 8.87 Gy/GBq Mean kidney-absorbed dose was 0.30 Gy/GBq Mean salivary gland-absorbed dose was 0.13 Gy/GBq The tumour:kidney ratio was 32.09 The tumour:salivary gland ratio was 73.19 An additional "anatomy-based" dosimetry evaluation was also performed, which used tumour volumes defined only on CT scan by a blinded radiologist, thereby capturing all regions of the tumour irrespective of uptake of the drug. In this analysis, the T:K and T:S ratios were 9 and 19, respectively. David Gauden DPhil, CEO of Blue Earth Therapeutics, said, "Numerous studies across various cancer types have shown the therapeutic value of delivering high radiation doses to tumours. At the same time, due to the risk of normal organ toxicity, one cannot simply administer unlimited amounts of radioactivity to patients. The solution is to develop therapeutic agents that improve the tumour:normal organ ratios so that the proportion of injected radioactivity reaching the tumors is scaled up to maximise efficacy. The Phase 1 dosimetry data being presented here at SNMMI is an important validation of the concept that improved agents are possible. We look forward to the clinical efficacy results from the ongoing Phase 2 portion of the trial. In this phase, we may begin to see benefits driven by the unique properties of the rhPSMA molecule. Additionally, the novel dosing regimen, which is designed to deliver higher cumulative doses of radioactivity with front-loading in the early treatment cycles, could provide further therapeutic advantage." About metastatic prostate cancer In 2025 it is estimated that there will be 50,055 new cases of metastatic prostate cancer in the United States (de novo diagnoses plus recurrence from earlier stage diagnoses).1 Five-year survival for newly diagnosed metastatic prostate cancer is low, 36.6%.2 While death rates from prostate cancer have declined over the past three decades2, there is still considerable room to improve patient outcomes. About Radiohybrid Prostate–Specific Membrane Antigen (rhPSMA) rhPSMA compounds are referred to as radiohybrid ("rh"), as each molecule possesses four distinct domains. The first consists of a Prostate–Specific Membrane Antigen–targeted receptor ligand. It is attached to two labelling moieties which may be radiolabeled with diagnostic isotopes such as 18F or 68Ga for PET imaging, or with therapeutic isotopes such as 177Lu or 225Ac for radioligand therapy, all of which are joined together by a modifiable linker which can be used to modulate important pharmacokinetic characteristics. Radiohybrid PSMA offers the potential for targeted treatment for men with prostate cancer and originated at the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and has sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. About Blue Earth Therapeutics Blue Earth Therapeutics is a clinical stage company dedicated to advancing next-generation targeted radiotherapeutics to treat patients who have cancer and has been incubated within the Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline initially focused on prostate cancer. For more information, please visit: About Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is a world–leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X–ray imaging (including Computed Tomography–CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose–management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting–edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: Gallichio L et al, JNCI J Natl Cancer Inst (2022) 114(11): djac158 SEER 22 database, Contact: For Blue Earth TherapeuticsRobert Dann, Vice President, Strategy & Planning+1 (617) UKBET-rh-2500018 | June 2025 View original content to download multimedia: SOURCE Blue Earth Therapeutics LTD Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Garching / Munich, Germany, June 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an oral presentation and Satellite Symposium at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held from June 21 – June 24, 2025 in New Orleans, Louisiana. Details of the Oral PresentationThe data will be presented by Dr. Thomas A. Hope, MD, Chief of Nuclear Medicine at the San Francisco VA Medical Center and Vice Chair of Clinical Operations and Strategy in the Department of Radiology at UCSF in an oral presentation titled, 'Predicting the [177Lu]Lu-edotreotide uptake in tumors using pre-therapeutic Ga-68 PET/CT imaging', on Sunday, June 22 in the Neuroendocrine - Oncology Clinical Diagnosis and Therapy session from 3:30 – 4:45 pm CDT. The presentation will provide an analysis on the 177Lu-edotreotide tumor uptake and its predictability based on pre-therapeutic SSTR PET/CT imaging and other factors. Symposium DetailsThe symposium, 'Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry,' will take place on Sunday June 22, from 6:30 pm – 7:30 pm CDT. The symposium will feature an overview of the GEP-NET treatment landscape, including findings from the Phase 3 COMPETE trial, and perspectives on dosimetry standardization today and in the future. COMPETE evaluated n.c.a 177Lu-edotreotide (also known as ITM-11) in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and ITM announced the positive Phase 3 results in March 2025. Date and Time: Sunday, June 22, from 6:30 pm – 7:30 pm CDTLocation: Ernest N. Morial Convention Center, New Orleans, LA; Room R04-R05Speakers and Topics: GEP-NET treatment landscape, COMPETE trial results, and COMPOSE trial designJonathan Strosberg, MD; Section Head, Neuroendocrine Division Program Chair, Gastrointestinal Department Oncology Research Program Moffitt Cancer Center COMPETE dosimetry sub-study and the evolution of dosimetryJohn Sunderland, PhD; Professor of Radiology Nuclear Medicine Division University of Iowa Dr. Celine Wilke Participates in Entrepreneur's PanelAs part of the SNMMI conference, Dr. Celine Wilke, ITM's Chief Medical Officer will participate in the 'Entrepreneur's Panel: Community Based Sites – Accelerating Clinical Trials and Expanding Access,' on Saturday, June 21, from 3:30 – 4:45 pm will further be present at the conference with a booth (booth number: 1001) providing information on the company's latest innovations in radiopharmaceutical therapy (RPT), its pipeline of RPT therapeutics and the company's capabilities to produce high-quality medical radioisotopes for global partners and its own pipeline. About the COMPETE TrialThe COMPETE trial evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@ Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@ Attachment 20250613_ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
